Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
ConvaTec ( (GB:CTEC) ) just unveiled an update.
Convatec Group has announced that Professor Constantin Coussios OBE will step down as a non-executive director on 30 April 2026 following his appointment as Pro-Vice-Chancellor for Innovation at the University of Oxford. During his tenure since 2020, he played a key role in reshaping the company’s R&D, helping compress product development cycle times, strengthen its innovation pipeline and support an innovation-led turnaround.
The company highlighted that its new product vitality index has risen from about 10% to 30%, with 16 product launches underway since 2022, underpinning what the board describes as the strongest pipeline in Convatec’s history. As a result of his departure, the previously proposed AGM resolution to re-elect Professor Coussios has been withdrawn, though all other resolutions and proxy votes remain unaffected, indicating limited governance disruption despite the board change.
The most recent analyst rating on (GB:CTEC) stock is a Buy with a £3.22 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
Spark’s Take on CTEC Stock
According to Spark, TipRanks’ AI Analyst, CTEC is a Neutral.
The score is driven primarily by solid underlying financial performance (growth, improving operating margins, positive free cash flow) and supportive guidance for continued growth and margin expansion. This is tempered by increased leverage and notable operational/regulatory risks flagged on the call, while valuation looks expensive and technicals appear near overbought despite an uptrend.
To see Spark’s full report on CTEC stock, click here.
More about ConvaTec
Convatec Group is a global medical products and technologies company focused on solutions for managing chronic conditions, with leading positions in advanced wound care, ostomy care, continence care and infusion care. The FTSE 100 constituent operates in around 90 countries with more than 10,000 employees and generated over $2 billion in revenue in 2025, providing products aimed at infection prevention, wound treatment, improved patient outcomes and lower care costs.
Average Trading Volume: 10,136,381
Technical Sentiment Signal: Buy
Current Market Cap: £4.56B
See more insights into CTEC stock on TipRanks’ Stock Analysis page.